Cited 5 times in
Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김자경 | - |
dc.contributor.author | 유정환 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 이정일 | - |
dc.date.accessioned | 2018-07-20T07:57:32Z | - |
dc.date.available | 2018-07-20T07:57:32Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160707 | - |
dc.description.abstract | BACKGROUND: Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C. METHODS: All consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital were enrolled. RESULTS: A total of 142 patients (male 53, female 89) were tested for RAVs. The average age of the patients was 58 years. Liver cirrhosis was found in 34.5% (49/142) of patients, and 19.0% (29/142) of patients had previously undergone interferon-based treatment. Twenty-nine patients (20.4%) had RAVs (Y93 or L31). Y93H, L31, or Y93H with L31 were detected in 22 (15.5%), 8 (5.6%), and 1 (0.7%) patients, respectively. The presence of RAV was not affected by previous interferon-based treatment or by the existence of liver cirrhosis. Among 113 patients without baseline NS5A RAVs, 72 patients started daclatasvir (DCV) + asunaprevir (ASV) treatment and 95% (68/72) patients achieved virologic response at week 4. Virologic response at end of treatment and sustained virologic response at 12 weeks after treatment were achieved by 94% (68/72) and 94% (68/72), respectively. CONCLUSIONS: In Korean patients with genotype 1b CHC, 20.4% (29 of 142) of patients showed RAVs against NS5A inhibitors. Patient without RAVs who received treatment with DCV + ASV showed high virologic response rates in Korea. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | England | - |
dc.publisher | 1743-422X | - |
dc.relation.isPartOf | VIROLOGY JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Base Sequence | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Drug Resistance, Viral/drug effects* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepacivirus/classification* | - |
dc.subject.MESH | Hepacivirus/genetics | - |
dc.subject.MESH | Hepacivirus/isolation & purification | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis C, Chronic/epidemiology | - |
dc.subject.MESH | Hepatitis C, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imidazoles/therapeutic use* | - |
dc.subject.MESH | Interferons/therapeutic use | - |
dc.subject.MESH | Isoquinolines/therapeutic use* | - |
dc.subject.MESH | Liver Cirrhosis/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | RNA, Viral/isolation & purification | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Sulfonamides/therapeutic use* | - |
dc.subject.MESH | Sustained Virologic Response | - |
dc.subject.MESH | Treatment Failure | - |
dc.subject.MESH | Viral Nonstructural Proteins/drug effects* | - |
dc.subject.MESH | Viral Nonstructural Proteins/genetics* | - |
dc.title | Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jung Hwan Yu | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Ja Kyung Kim | - |
dc.identifier.doi | 10.1186/s12985-017-0826-1 | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A04610 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03122 | - |
dc.relation.journalcode | J03383 | - |
dc.identifier.eissn | 1743-422X | - |
dc.identifier.pmid | 28836992 | - |
dc.subject.keyword | Asunaprevir | - |
dc.subject.keyword | Chronic hepatitis C | - |
dc.subject.keyword | Daclatasvir | - |
dc.subject.keyword | Direct-acting antivirals | - |
dc.contributor.alternativeName | Kim, Ja Kyung | - |
dc.contributor.alternativeName | Yu, Jung Hwan | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.alternativeName | Lee, Jung Il | - |
dc.contributor.affiliatedAuthor | Kim, Ja Kyung | - |
dc.contributor.affiliatedAuthor | Yu, Jung Hwan | - |
dc.contributor.affiliatedAuthor | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | Lee, Jung Il | - |
dc.citation.volume | 14 | - |
dc.citation.number | 164 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.identifier.bibliographicCitation | VIROLOGY JOURNAL, Vol.14(164) : 1-9, 2017 | - |
dc.identifier.rimsid | 43770 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.